SHORT-TERM TREATMENT OF RELAPSING REMITTING MULTIPLE SCLEROSIS PATIENTS WITH INTERFERON (IFN)-β1B TRANSIENTLY INCREASES THE BLOOD LEVELS OF INTERLEUKIN (IL)-6, IL-10 AND IFN-γ WITHOUT SIGNIFICANTLY MODIFYING THOSE OF IL-1β, IL-2, IL-4 AND TUMOUR NECROSIS FACTOR-α

Abstract

We have studied the impact of short-term treatment with interferon (IFN)-β1b of relapsing remitting (RR) multiple sclerosis (MS) patients' blood levels of type 1 and type 2 cytokines such as IFN-γ, interleukin (IL)-1β, IL-2, IL-4, IL-6, IL-10 and tumour necrosis factor (TNF)-α. These cytokines were measured by solid-phase ELISA. Serum samples were obtained prior to, and 2 and 12hours after beginning of the treatment and 48h after the last of 5 s.c. injections with 8 million IU IFN-β1b given on alternate days for 10 days. The treatment was found to increase the circulating levels of IL-2, IL-6, IL-10 and IFN-γ at some of the time points considered, with the effect acquiring statistical significance for IL-6, IL-10 and IFN-γ. The blood levels of IL-1β, IL-4 and TNF-α remained below the limit of sensitivity of the assays at any of the time points considered. If this in vivo study mirrors the impact of IFN-β1b on MS patients' immune cells, these data demonstrate an activation of the immune system upon early treatment with the drug that does not lead to either type 1 or type 2 cytokine prevalence.